Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals announces public offering of common stock

Published in Healthcare Finance, Tax and Law Weekly, April 26th, 2006

Amylin Pharmaceuticals, Inc., (AMLN) announced that it has filed a preliminary prospectus supplement to a shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 8,500,000 shares of its common stock.

The underwriters will be granted the right to purchase up to an additional 1,275,000 shares of common stock to cover over-allotments, if any. All of the shares are being sold by Amylin Pharmaceuticals.

Morgan Stanley & Co. Incorporated is acting as the sole bookrunning and joint lead manager for the offering. Goldman, Sachs & Co. is acting as a non-bookrunning joint-lead manager of the offering....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2006-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry